Tempol Induces Oxidative Stress, ER Stress and Apoptosis via MAPK/Akt/mTOR Pathway Suppression in HT29 (Colon) and
Gorkem Ozdemir1, Halil Mahir Kaplan2
1Department of Gastroenterological Surgery, Adana City Training and Research Hospital, 01230 Adana, Turkey.
Abstract:
Tempol is a synthetic antioxidant that shows promise in preclinical cancer studies by inhibiting growth and inducing apoptosis. Given that the Mitogen-Activated Protein Kinase (MAPK) and Protein Kinase B/Mammalian Target of Rapamycin (Akt/mTOR) signaling pathways are frequently dysregulated in gastric and colon cancers and contribute to their progression, we investigated Tempol's anti-cancer potential in HT29 (colon) and CRL-1739 (gastric) cancer cells. Cells were treated with 2 mM Tempol for 48 h, with untreated cells as controls. We evaluated apoptosis (Bax, cleaved caspase-3, and Bcl-2), key signaling pathway activity (p-ERK, p-JNK, p-AKT, and p-mTOR), and levels of stress- and apoptosis-related proteins (WEE1, GADD153, GRP78, and AIF). Tempol significantly increased pro-apoptotic Bax and cleaved caspase-3 (p < 0.0001) and decreased anti-apoptotic Bcl-2 (p < 0.0001) in both cell lines. Furthermore, Tempol markedly reduced the activity of p-ERK, p-JNK, p-AKT, and p-mTOR (p < 0.0001) and significantly increased the protein levels of WEE1, GADD153, GRP78, and AIF (p < 0.0001). Tempol treatment also led to a significant increase in total oxidant status and a decrease in total antioxidant status. In conclusion, our findings suggest that Tempol exhibits its anti-cancer activity through multiple interconnected mechanisms, primarily inducing apoptosis and oxidative stress, while concurrently suppressing pro-survival signaling pathways. These results highlight Tempol's potential as a therapeutic agent for gastric and colon cancers.
Insights
The synthetic antioxidant Tempol effectively combats colon and gastric cancer cells by inducing apoptosis and oxidative stress. It also suppresses key pro-survival signaling pathways, highlighting its therapeutic potential.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Gastric and colon cancers often exhibit dysregulated Mitogen-Activated Protein Kinase (MAPK) and Protein Kinase B/Mammalian Target of Rapamycin (Akt/mTOR) signaling pathways.
- These pathways contribute significantly to cancer progression and are potential therapeutic targets.
Purpose of the Study:
- To investigate the anti-cancer potential of Tempol, a synthetic antioxidant, in human colon (HT29) and gastric (CRL-1739) cancer cell lines.
- To elucidate the mechanisms underlying Tempol's anti-cancer effects, focusing on apoptosis induction and modulation of key signaling pathways.
Main Methods:
- Treatment of HT29 and CRL-1739 cells with 2 mM Tempol for 48 hours.
- Evaluation of apoptosis markers (Bax, cleaved caspase-3, Bcl-2), signaling pathway activity (p-ERK, p-JNK, p-AKT, p-mTOR), and stress/apoptosis-related proteins (WEE1, GADD153, GRP78, AIF).
- Assessment of total oxidant status and total antioxidant status.
Main Results:
- Tempol significantly increased pro-apoptotic proteins (Bax, cleaved caspase-3) and decreased anti-apoptotic protein (Bcl-2) in both cell lines (p < 0.0001).
- Tempol markedly reduced the activity of key signaling pathways (p-ERK, p-JNK, p-AKT, p-mTOR) (p < 0.0001).
- Tempol treatment increased levels of WEE1, GADD153, GRP78, and AIF, alongside increased oxidant status and decreased antioxidant status.
Conclusions:
- Tempol demonstrates anti-cancer activity through multiple mechanisms, including apoptosis induction and oxidative stress.
- Tempol effectively suppresses pro-survival signaling pathways implicated in gastric and colon cancer progression.
- These findings support Tempol's potential as a therapeutic agent for gastric and colon cancers.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Regulation of the Unfolded Protein Response
PI3K/mTOR/AKT Signaling Pathway
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
MAPK Signaling Cascades
The Intrinsic Apoptotic Pathway


